Valeant Eyes $296M Prostate Drug In 1st Post-Allergan Play
In its first major deal since Allergan Inc. thwarted its blockbuster takeover campaign last year, Valeant Pharmaceuticals International Inc. said late Thursday it has struck a tentative agreement to buy a...To view the full article, register now.
Already a subscriber? Click here to view full article